RESEARCH ARTICLE

Sexual and bladder dysfunction in male ketamine abusers: A large-scale questionnaire study

Stephen She-Dei Yang1,2, Mei-Yu Jang3, Kau-Han Lee4, Wen-Tsang Hsu5, Yi-Chu Chen1, Wan-San Chen1, Shang-Jen Chang1,2*

1 Department of Urology, Taipei Tzu Chi Hospital, New Taipei, Taiwan, 2 School of Medicine, Buddhist Tzu Chi University, Hualien, Taiwan, 3 Department of Urology, Kaohsiung Municipal Hsia-Kang Hospital, Kaohsiung City, Taiwan, 4 Division of Urology, Department of Surgery, Chi Mei Medical Center, Tainan City, Taiwan, 5 Department of Urology, Keelung Hospital, Ministry of Health and Wealthfare, Keelung City, Taiwan

* krissygnet@gmail.com

Abstract

Purpose

To evaluate the prevalence of lower urinary tract symptoms (LUTS) and erectile dysfunction (ED) in the illicit male ketamine abusers (KA).

Materials and methods

The male street KAs caught by policemen and patients visiting urologic clinics were invited to answer a structured questionnaire including demographic data, illicit drug use related details (duration, frequency, dosage and abstinence status), international prostate symptoms score (IPSS), interstitial cystitis symptoms and problem index (ICSI and ICPI) and International index of erectile function (IIEF-5). Erectile dysfunction was defined as IIEF-5 \( \leq 21 \).

Results

Finally, we included 1056 participants (993 street, 63 hospital KAs) with a mean age of 27.4 ± 6.2 years. ED presented in 30.8% of all KAs. and Hospital KAs were more subject to having ED than street KAs (69.6% vs. 28.0%, \( p < 0.01 \)). Multi-variate analysis revealed that risk factor for male ED were age \( \geq 30 \) years (OR = 1.765). Subgroup analysis on male street KAs disclosed that abstinence \( \geq 3 \) months is a protective factor for ED. Lower urinary tract symptoms (ICSI+ICPI \( \geq 12 \)) was prevalent in KAs and multivariate analysis disclosed that significant risk factors for LUTS (ICSI+ICPI \( \geq 12 \)) were age \( \geq 30 \) years, duration \( \geq 24 \) months and co-use of other illicit drugs.

Conclusions

Male ED and LUTS were frequently observed in the ketamine abusers. We suggested that street ketamine abuse should be considered in young men presented with ED and LUTS in the clinics.
**Introduction**

Ketamine is an antagonist of the N-methyl-D-aspartic acid (NMDA) receptor complex and is mainly used for anesthesia. Also, ketamine is also being studied as a treatment for mental disorders (i.e. depression[1] and pain[2]). However, it is now frequently used as a recreation drug due to its dissociative effect. In Taiwan, ketamine is classified as grade III illicit drug and was second to ecstasy as the most commonly consumed illegal drugs among young people[3]. Illicit ketamine use is associated with urological burden such as ketamine cystitis and erectile dysfunction[4–6]. Large surveys revealed 20–30% of ketamine abusers suffered with lower urinary tract symptoms due to ketamine cystitis (KC).

Erectile dysfunction (ED) is characterized by an inability to achieve and maintain penile erection for sexual performance. The relationship between illicit use of ketamine and male sexual function was less clear. Long-term administration of ketamine induced erectile dysfunction in rats. [7]. Suppiah et al[5] reported that half of 127 Malaysians, mostly ethnic Chinese, using ketamine and polydrugs admitted erectile dysfunction. Recently, animal study showed that ketamine could induce erectile dysfunction in male rats[8]. Up to date, there was no large scale study using validated questionnaire to survey erectile dysfunction in male KAs.

A group of experts in Taiwan met and reached a general consensus on the recommended assessment of ketamine associated uropathy[9]. International Prostate Symptoms Score (IPSS), Interstitial Cystitis Symptoms and Problem Index (ICSI and ICPI) were recommended to assess LUTS in KAs because these questionnaires have been widely used by Taiwanese urologists[10]. Herein, we reported the prevalence of erectile dysfunction and LUTS among street and hospital KAs. Risk factors of erectile dysfunction and LUTS were analyzed and reported.

**Materials and methods**

The study was approved by ethic committee of Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation. Ketamine is graded as level III illicit drug in Taiwan. Street KAs caught by policemen were requested to attend an educational course for 6–8 hours in Taiwan[3]. If there is concomitant use of higher level of illicit drugs (i.e. Heroin, morphine, opiate, cocaine, amphetamine, NMDA, and marijuana), they will be detained in a Drug Abstention and Treatment Center for detoxication for at most 2 months[11]. Therefore, the study included only those with ketamine and those with higher level of illicit drug were not included in the study. The study participants comprised men aged≥ 18 years. During the educational courses, all participants were given a verbal explanation of the study. After the participants completed the written informed consents, they were invited to answer a structured questionnaire anonymously, which included demographic data, history of alcohol consumption, smoking, other illicit drug abuse in addition to ketamine (i.e., Heroin, morphine, opiate, cocaine, amphetamine, NMDA, and marijuana etc.), visual pain score (0–10), International Prostate Symptom Score (IPSS), brief form International Index of Erectile Function (IIEF-5) and the Interstitial Cystitis Symptom Index (ICSI) and Problem Index (ICPI)[10] questionnaires. The same questionnaires were answered by patients visiting urologic clinics for management of LUTS.

**Dosage of ketamine, duration and abstinence status of ketamine**

Participants were then asked to answer the average daily dosage of ketamine they used (g/day), the route of ketamine use (oral ingestion, inhalation, snorting or smoking cigarettes with ketamine), and the duration of ketamine use (months). The participant was asked whether they had quit the ketamine or not. If the participant had quit ketamine, the period of ketamine abstinence was recorded (months).
Erectile dysfunction
The sexual function was evaluated with the IIEF-5. Response options are based on rating scales from 1 to 5. The responses are summed resulting in a total IIEF-5 score ranging from 5 to 25. A score of 21 or lower is regarded as having erectile dysfunction (ED). ED can be classified into five severity grades: absence of ED (IIEF-5 score 22–25), mild (17–21), mild to moderate (12–16), moderate (8–11), and severe (5–7)[12]

Lower urinary tract symptoms
The lower urinary tract symptoms were evaluated with the International Prostate Symptom Score (IPSS), Interstitial Cystitis Symptom Index (ICSI) and Problem Index (ICPI)[8] An IPSS of 8 or more is regarded as abnormal. The original goal of ICSI and ICPI I questionnaire is to evaluate and diagnose patients with interstitial cystitis and each questionnaire contains four questions related to urinary and pain symptoms. A score of (ICSI + ICPI) ≥12 points is regarded as abnormal. The Symptom Index included four symptoms: 1. whether the patient feels the need to urinate with little or no warning 2. has to urinate more frequently than every 2 hours, 3. needs to get up during the night to urinate, and 4. has pain in the bladder. The Problem Index evaluate: 1. urinary frequency during the day, 2. urinary frequency at night, 3. the need to urinate with little or no warning, and 4. burning, pain, discomfort, or pressure on the bladder.

Statistics
Data were expressed as mean ± standard deviation and were analyzed by commercial statistical software (SAS, version 9.4, USA). Demographic and voiding parameters were compared via an independent sample t test (continuous demographic variables), a χ2 test (nominal data), and a Mann-Whitney U test (ordinal data). Multivariate logistic regression was used to evaluate the risk factors, ie. Age, cigarette smoking (yes vs. no), alcohol consumption (yes vs. no), dosage of ketamine (dosage >2 or ≤ 2 g), and duration of illicit ketamine use (months), route of ketamine administration (smoking ketamine cigarette vs. others), Co-use of other illicit drugs (yes vs. no) and abstinence period of illicit ketamine for male sexual dysfunction (IIEF-5 = 21). For all tests, a p-value of less than 0.05 was regarded as significant.

Results
Between 2016 and 2017, 993 street KAs and 63 hospital KAs were enrolled. Mean age of the subjects are 22.76 ± 6.4 years. Table 1 summarizes the demographic data and results of questionnaire. The mean duration and dosage of illicit ketamine use is 31.6±37.3 months and 2.20 ±2.89 g/day. KAs enrolled from hospitals had higher average daily dose and longer period of using of drugs, higher score of LUTS (IPSS, ICSI, ICPI), higher pain score, and lower score of IIEF-5 than those from street.

Erectile dysfunction
Complete IIEF-5 was replied in 804 male KAs of whom 30.8% with IIEF-5 ≤21 were regarded as having erectile dysfunction (Table 2). ED was more commonly frequently observed in hospital than street KAs (69.6% vs. 27.9%, p<0.001). Univariate analysis revealed that age ≥30 years and duration of ketamine use were significant risk factors for ED in ketamine abuser. Also, abstinence of ketamine is a protective factor for erectile function among the participants. However, average daily dose, route of ketamine use, cigarette and alcohol consumption did not pose significant effects on ED. Multi-variate analysis disclose that the only risk factor for
ED in all male KAs were $\geq 30$ years (Table 3). Subgroup analysis on male street KAs disclosed that age $\geq 30$ years is a risk factor of ED and abstinence $\geq 3$ months is a protective factor (Table 4).

**Lower urinary tract symptoms**

LUTS (ICSI+ICPI $\geq 12$) is prevalent in KAs although these participants are young men and are more frequently observed in the hospital KAs than street KA (77.6% vs. 6.7%, p $< 0.001$). Table 5 lists the univariate and multivariate analysis for risk factor of lower urinary tract symptoms. Univariate analysis revealed that age $\geq 30$ years, duration of ketamine use $\geq 24$ months, average dosage $\geq 2$ g and co-use of other illicit drugs were significant risk factors for ED in ketamine abuser. Multivariate analysis disclosed that significant risk factors for LUTS (ICSI +ICPI $\geq 12$) were age $\geq 30$ years, duration $\geq 24$ months and co-use of other illicit drugs. Average dosage $\geq 2$ g also pose impact on LUTS despite insignificant on multivariate analysis.

**Correlations between sexual and bladder dysfunction in all ketamine abusers**

Sum score of ICSI plus ICPI was negatively associated with IIEF-5 in all male KAs (p $< 0.0001$, Fig 1A) and male street KAs (p $< 0.0001$, Fig 1B).

**Discussion**

Up to date, this is the largest case series to report sexual dysfunction and lower urinary tract symptoms in male illicit ketamine abusers which comprised those caught by policemen or

| Table 1. Demographic data and results of questionnaires in street and hospital male ketamine abusers. |
|------------------------------------------------------------|-------------------------------------------------------------|
| Total | Street Abusers | Hospital Abusers | p-value |
| N | 1056 | 993 (94.03%) | 63 (5.97%) | 0.0078* |
| Age in years | 27.76$\pm$6.40 | 27.59$\pm$6.30 | 29.82$\pm$7.24 | 0.0078* |
| Duration (months) | 31.64$\pm$37.33 | 30.36$\pm$35.85 | 51.41$\pm$51.79 | 0.0078* |
| Daily dose (g) | 2.20$\pm$2.89 | 2.04$\pm$2.73 | 4.11$\pm$3.98 | <0.0001* |
| IPSS score | 3.67$\pm$6.37 | 2.71$\pm$4.43 | 17.40$\pm$11.89 | <0.0001* |
| ICSI score | 2.023$\pm$3.40 | 1.50$\pm$2.26 | 10.33$\pm$6.53 | <0.0001* |
| ICPI score | 1.90$\pm$3.76 | 1.37$\pm$2.86 | 10.11$\pm$6.00 | <0.0001* |
| IIEF-5 score | 22.10$\pm$4.13 | 22.35$\pm$3.97 | 18.76$\pm$4.62 | <0.0001* |
| Pain score | 0.58$\pm$1.67 | 0.36$\pm$1.15 | 4.10$\pm$3.70 | <0.0001* |

*: a p-value of less than 0.05 was regarded as significant.

https://doi.org/10.1371/journal.pone.0207927.t001

| Table 2. Grade of erectile dysfunction by IIEF-5 in all ketamine abusers. |
|------------------------------------------------------------|-------------------------------------------------------------|
| N | All | Street KA | Hospital KA | p-value |
| N | 804 | 748 | 56 |  |
| Normal (22–25) | 556 (69.15%) | 539 (72.06%) | 17 (30.36%) | <0.0001* |
| Mild (17–21) | 176 (21.89%) | 155 (20.72%) | 21 (37.50%) |  |
| Mild to moderate (12–16) | 39 (4.85%) | 26 (3.48%) | 13 (23.21%) |  |
| Moderate (8–11) | 15 (1.87%) | 11 (1.47%) | 4 (7.14%) |  |
| Severe ($\leq 7$) | 18 (2.24%) | 17 (2.27%) | 1 (1.79%) |  |

*: a p-value of less than 0.05 was regarded as significant.

https://doi.org/10.1371/journal.pone.0207927.t002
visiting urologic clinics for managements of LUTS. Compared to street KAs, hospital KAs had higher average daily dose, longer period of ketamine abuse, higher score of LUTS and lower score in sexual function (Table 1). Male erectile dysfunction as defined by IIEF-5 \( \leq 21 \) was reported in 30.8% of all KAs (Table 2), which was higher than the reported prevalence of healthy Taiwanese young men in which were 11.9% and 17.6%, respectively[11, 13]. Male ED was more frequently observed in hospital than street KAs (69.6% vs. 27.1%, \( p < 0.0001 \) especially more mild to moderate ED was observed. Though most male street KAs were graded as mild ED, about 1/3 of male hospital KAs had higher grade of ED (Table 2). Recently, Suppiah et al used an yes or no question to define ED and reported that ED was present among half of

| Variable                          | IIEF-5 \( > 21 \) | IIEF-5 \( \leq 21 \) | cOR 1 | aOR* 1 |
|-----------------------------------|-----------------|-----------------|-------|--------|
| Age in years                      |                 |                 |       |        |
| <25                               | 214 (76.16%)    | 67 (23.84%)     | 1     | 1      |
| 25–30                             | 176 (71.84%)    | 69 (28.16%)     | 1.252 (0.847–1.851) | 1.153 (0.728–1.827) |
| >30                               | 165 (59.57%)    | 112 (40.43%)    | 2.168 (1.506–3.121)* | 2.092 (1.367–3.200)* |
| Duration (months)                 |                 |                 |       |        |
| < = 12                            | 225 (73.29%)    | 82 (26.71%)     | 1     | 1      |
| 12–24                             | 52 (61.90%)     | 32 (38.10%)     | 1.689 (1.016–2.806)* | 1.535 (0.897–2.625) |
| > = 24                            | 143 (64.71%)    | 78 (35.29%)     | 1.497 (1.029–2.176)* | 1.296 (0.865–1.942) |
| Missing                           | 135             | 56              |       |        |
| Average daily dose                |                 |                 |       |        |
| <2 (g)                            | 340 (68.14%)    | 159 (31.86%)    | 1     |        |
| >2 (g)                            | 130 (68.78%)    | 59 (31.22%)     | 0.971 (0.677–1.392) |        |
| Missing                           |                 |                 |       |        |
| Period of abstinence in months    |                 |                 |       |        |
| 0 Still use                       | 52 (61.90%)     | 32 (38.10%)     | 1     | 1      |
| <3                                | 55 (67.07%)     | 27 (32.93%)     | 0.798 (0.422–1.509) | 0.836 (0.417–1.673) |
| 3–6                               | 68 (77.27%)     | 20 (22.73%)     | 0.478 (0.246–0.930)* | 0.507 (0.239–1.072) |
| >6                                | 336 (69.14%)    | 150 (30.86%)    | 0.725 (0.449–1.173) | 0.822 (0.484–1.398) |
| Missing                           | 36              | 16              |       |        |
| Route of ketamine use             |                 |                 |       |        |
| Smoking ketamine cigarette        | 490 (69.31%)    | 217 (30.69%)    | 1     |        |
| Others (snorting or oral ingestion)| 29 (65.91%)    | 15 (34.09%)     | 1.168 (0.614–2.223) |        |
| Missing                           | 36              | 16              |       |        |
| Co-use of other illicit drugs     |                 |                 |       |        |
| No                                | 487 (70.17%)    | 207 (29.83%)    | 1     |        |
| Yes                               | 40 (59.70%)     | 27 (40.30%)     | 1.588 (0.949–2.657) |        |
| Missing                           | 28              | 14              |       |        |
| Tobacco smoking                   |                 |                 |       |        |
| No                                | 35 (66.04%)     | 18 (33.96%)     | 1     |        |
| Yes                               | 519 (69.76%)    | 225 (30.24%)    | 0.843 (0.467–1.520) |        |
| Missing                           | 1               | 5               |       |        |
| Alcohol                           |                 |                 |       |        |
| No                                | 210 (67.74%)    | 100 (32.26%)    | 1     |        |
| Yes                               | 340 (70.25%)    | 144 (29.75%)    | 0.889 (0.654–1.210) |        |
| Missing                           | 5               | 4               |       |        |

*p < 0.05.

https://doi.org/10.1371/journal.pone.0207927.t003
Malaysians who used ketamine and poly-drugs[14]. In the ketamine-treated rats, long-term ketamine administration caused significantly decreased erectile responses, decreased smooth muscle content, reduced nNOS expression, increased iNOS content and increased corpus cavernosum apoptosis when compared with controls[7]. This may partly explain the reasons why ketamine could cause erectile dysfunction in young men. Similarly, illicit use of amphetamine was associated with erectile dysfunction[11]. High prevalence of erectile dysfunction in ketamine, amphetamine and other substance abuse may partly explain the significant misuse of sildenafil in London nightclubs[15].

Higher average daily dose and longer duration of ketamine abuse may partly explain the reasons of male ED in hospital KAs (Table 1) Univariate analysis disclosed risk factors of male sexual and bladder dysfunction in male ketamine abusers.

### Table 4. Risk factors of IIEF \( < = 21 \) among only street ketamine abusers.

| Variable | IIEF\(>21\) | IIEF\(< = 21\) | cOR | aOR$^a$ |
|----------|-------------|----------------|------|---------|
| **Age in years** | | | | |
| \(< 25\) | 210 (78.07%) | 59 (21.93%) | 1 | 1 |
| \(25–30\) | 169 (72.84%) | 63 (27.16%) | 1.327 (0.881–1.997) | 1.310 (0.855–2.007) |
| \(\geq 30\) | 159 (64.63%) | 87 (35.37%) | 1.947 (1.319–2.875)$^*$ | 2.015 (1.341–3.026)$^*$ |
| **Duration (months)** | | | | |
| \(< 12\) | 222 (74.75%) | 75 (25.25%) | 1 | |
| \(12–24\) | 52 (65.00%) | 28 (35.00%) | 1.594 (0.939–2.705) | |
| \(\geq 24\) | 135 (69.95%) | 58 (30.05%) | 1.272 (0.849–1.905) | |
| **Average daily dose** | | | | |
| \(< 2\) (g) | 337 (70.21%) | 143 (29.79%) | 1 | |
| \(\geq 2\) (g) | 120 (73.17%) | 44 (26.83%) | 0.864 (0.581–1.285) | |
| **Period of abstinence in months** | | | | |
| \(0\) Still use | 50 (64.94%) | 27 (35.06%) | 1 | 1 |
| \(< 3\) | 53 (69.74%) | 23 (30.26%) | 0.804 (0.408–1.582) | 0.735 (0.370–1.459) |
| \(3–6\) | 68 (80.95%) | 16 (19.05%) | 0.436 (0.212–0.893)$^*$ | 0.394 (0.190–0.814)$^*$ |
| \(\geq 6\) | 328 (72.09%) | 127 (27.91%) | 0.717 (0.430–1.195) | 0.668 (0.398–1.121) |
| **Route of ketamine use** | | | | |
| Smoking ketamine cigarette | 484 (71.92%) | 189 (28.08%) | 1 | |
| Others (snorting or oral ingestion) | 23 (74.19%) | 8 (25.81%) | 0.891 (0.392–2.026) | |
| **Co-use of other drugs** | | | | |
| No | 477 (72.05%) | 185 (27.95%) | 1 | |
| Yes | 36 (75.00%) | 12 (25.00%) | 0.859 (0.438–1.688) | |
| **tobacco smoking** | | | | |
| No | 33 (66.00%) | 17 (34.00%) | 1 | |
| Yes | 505 (72.45%) | 192 (27.55%) | 0.738 (0.402–1.356) | |
| **Alcohol** | | | | |
| No | 202 (70.38%) | 85 (29.62%) | 1 | |
| Yes | 332 (72.97%) | 123 (27.03%) | 0.880 (0.635–1.221) | |

*a*p < 0.05.

https://doi.org/10.1371/journal.pone.0207927.t004
ED were age ≥30 years and duration of abuse ≥12 months, while ketamine abstinence was a protective factor (Table 3). Multiple variate analysis showed that only age ≥30 years was risk factors for male ED. The reason why age as a risk factor of ED in KAs was unknown yet, though older age may be associated with longer duration and higher dose of ketamine abuse. Further studies on the age and effects of ketamine should be explored. Since our subgroup analysis on male street KAs disclosed that risk factors for ED were age ≥30 years and abstinence ≥3 months is a protective factor (Table 4), more studies are required to prove that abstinence from ketamine does improve erectile function. Among these young participants, alcohol, cigarette smoking, route of ketamine administration and co-use of other illicit drugs did pose significant effect on ED.

Significant risk factors for having LUTS were older age, longer duration of ketamine use, and higher dosage of ketamine use which were in line with previous studies. Co-use of other illicit drugs also pose significant effects on LUTS (Table 5) Previous case reports mostly enrolled participants of high dose (≥2 g) and long duration of ketamine abuse[16–18]. The

---

Table 5. Risk factors (ICSI+ICP I \(\geq 12\)) in all male ketamine abusers.

| Variable                        | ICSI+ICP I \(< 12\) | ICSI+ICP I \(\geq 12\) | cOR  | aOR* |
|---------------------------------|---------------------|------------------------|------|------|
| **Age in years**                |                     |                        |      |      |
| <25                             | 275 (93.54%)        | 19 (6.46%)             | 1    | 1    |
| 25–30                           | 221 (91.32%)        | 21 (8.68%)             | 1.375 (0.721–2.622) | 1.422 (0.621–3.256) |
| >= 30                           | 232 (82.27%)        | 50 (17.73%)            | 3.119 (1.788–5.441)* | 3.805 (1.862–7.777)* |
| Missing                         | 152                 | 12                     |      |      |
| **Duration (months)**           |                     |                        |      |      |
| <= 12                           | 348 (95.08%)        | 18 (4.92%)             | 1    | 1    |
| 12–24                           | 92 (92.93%)         | 7 (7.07%)              | 1.471 (0.596–3.628) | 0.982 (0.364–2.649) |
| >= 24                           | 221 (81.55%)        | 50 (18.45%)            | 4.374 (2.487–7.691)* | 2.061 (0.999–4.253) |
| Missing                         | 219                 | 27                     |      |      |
| **Average daily dose**          |                     |                        |      |      |
| <2 (g)                          | 568 (94.35%)        | 34 (5.65%)             | 1    | 1    |
| >= 2 (g)                        | 188 (77.69%)        | 54 (22.31%)            | 4.799 (3.031–7.600)* | 3.721 (1.971–7.025)* |
| Missing                         | 124                 | 14                     |      |      |
| **Route of ketamine use**       |                     |                        |      |      |
| Smoking ketamine cigarette      | 657 (90.50%)        | 69 (9.50%)             | 1    |      |
| Others (snorting or oral ingestion) | 180 (88.24%)  | 24 (11.76%)            | 1.270 (0.776–2.078) |      |
| Missing                         | 43                  | 9                      |      |      |
| **Co-use of other drugs**       |                     |                        |      |      |
| No                              | 688 (91.13%)        | 67 (8.87%)             | 1    |      |
| Yes                             | 144 (84.71%)        | 26 (15.29%)            | 1.854 (1.139–3.018)* | 3.285 (1.587–6.801)* |
| Missing                         | 48                  | 9                      |      |      |
| **Smoking**                     |                     |                        |      |      |
| No                              | 55 (93.22%)         | 4 (6.78%)              | 1    |      |
| Yes                             | 823 (89.65%)        | 95 (10.35%)            | 1.587 (0.563–4.477)  |      |
| Missing                         | 2                   | 3                      |      |      |
| **Alcohol**                     |                     |                        |      |      |
| No                              | 322 (89.20%)        | 39 (10.80%)            | 1    |      |
| Yes                             | 551 (90.48%)        | 58 (9.52%)             | 0.869 (0.566–1.334)  |      |
| Missing                         | 7                   | 5                      |      |      |

* p<0.05.
relatively lower prevalence of LUTS among street KAs in the current study may be due to difference in questionnaire and duration of drug abuse. Our results on LUTS were similar to the reports by Chen et al [19] who used the same questionnaire to detect LUTS in KAs. They reported that among 143 participating ketamine users, 25 (17.5%) had LUTS. However, Chen et al did not report the LUTS in 118 street and 25 hospital ketamine abusers separately. Therefore, the true prevalence of LUTS in street KAs may be much lower. Shorter duration of street KAs in the current study (mean 32 months) may partly explain the lower incidence of LUTS in this study than Chen’s series (6.7% vs. 52%) in which a mean duration of 4 years was observed [1]. The significant association between erectile dysfunction and LUTS in male ketamine abusers can be attributed to longer duration and higher dose of ketamine which may have direct effects to both bladder and erectile functions.

The side effect of street ketamine may differ from the prescribed medical ketamine. The most commonly reported side effects associated with medical use of ketamine are psychiatric disorder, hypertension, nausea and vomiting[20]. Further studies are warranted to explore the differences in components between the street ketamine and medical-use ketamine.

Main limitation of the study lies in the volunteer filling in the questionnaire by the street KAs attending an educational course organized by the government. The variable dosage and duration of ketamine used within the period may lead to a significant bias. The self-reported dosage and a lack of objective parameters might result in measurement bias. Also, the study is lacking of normal control and whether ED or LUTS are more prevalent in ketamine abuser

Fig 1. Correlations between sexual (IIEF-5, Y axis) and bladder dysfunction (ICSI+ICP, X axis) in 734 male street and hospital ketamine abusers (1A) and 681 street ketamine abusers (1B).
remained lacking of strong evidence. We are now conducting a large-scale study to evaluate the lower urinary tract function including erectile function and lower urinary tract symptoms among the healthy young men. Hopefully, we can report the data in the near future. However, through the large scale study and comparisons between hospital KAs, the trend of more sexual dysfunction and LUTS in higher dose and longer duration abusers were confirmed indirectly. Secondly, we used the questionnaire to diagnose LUTS instead of using the more objective measurements, such as bladder diary and uroflowmetry. However, the large scale study made these diagnostic tests not feasible and a questionnaire (ICSI/ICPI) was used under the experts’ consensus. Thirdly, the comorbid psychiatric diseases were not recorded. Finally, the participants were not included through random sampling and therefore we enrolled a large number of study participants to overcome the bias.

Conclusions
Male sexual dysfunction and lower urinary tract symptoms was frequently observed in the street and hospital ketamine abusers. We suggested that street ketamine abuse should be considered in young men presented with ED and LUTS in the clinics.

IRB
The study was approved by ethic committee of Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation. IRB: 04-XD32-091

Supporting information
S1 File.
(XLS)

Acknowledgments
This study received financial support from the Food and Drug Administration, Ministry of Health and Welfare, Taiwan(grant number MOHW106-FDA-D-114-000634). We thank for their help in the conduction of the survey.

Author Contributions
Conceptualization: Stephen She-Dei Yang.
Data curation: Stephen She-Dei Yang, Mei-Yu Jang, Kau-Han Lee, Wen-Tsang Hsu.
Formal analysis: Stephen She-Dei Yang, Mei-Yu Jang, Wen-Tsang Hsu, Yi-Chu Chen.
Funding acquisition: Wan-San Chen.
Investigation: Kau-Han Lee, Wen-Tsang Hsu.
Methodology: Kau-Han Lee, Wen-Tsang Hsu.
Resources: Yi-Chu Chen.
Software: Yi-Chu Chen.
Supervision: Stephen She-Dei Yang.
Writing – original draft: Stephen She-Dei Yang, Shang-Jen Chang.
Writing – review & editing: Stephen She-Dei Yang.
References

1. Duman RS. Ketamine and rapid-acting antidepressants: a new era in the battle against depression and suicide. F1000Research. 2018; 7.

2. Allen CA, Conner R, Ivester JR Jr. Ketamine Infusions for Outpatient Pain Management: A Policy Development Project. Journal of infusion nursing: the official publication of the Infusion Nurses Society. 2018. https://doi.org/10.1097/NAN.0000000000000284 PMID: 28973538

3. Chen WJ, Ting TT, Chang CM, Liu YC, Chen CY. Ketamine use among regular tobacco and alcohol users as revealed by respondent driven sampling in Taipei: prevalence, expectancy, and users’ risky decision making. Journal of food and drug analysis. 2013; 21(4):S102–S5. https://doi.org/10.1016/j.jfda.2013.09.044 PMID: 25264412

4. Chu PS, Ma WK, Wong SC, Chu RW, Cheng CH, Wong S, et al. The destruction of the lower urinary tract by ketamine abuse: a new syndrome? BJU international. 2008; 102(11):1616–22. https://doi.org/10.1111/j.1464-410X.2008.07920.x PMID: 18680495

5. Shahani R, Streutker C, Dickson B, Stewart RJ. Ketamine-associated ulcerative cystitis: a new clinical entity. Urology. 2007; 69(5):S102–S5. https://doi.org/10.1016/j.urology.2007.09.044 PMID: 25264412

6. Robles-Martinez M, Abad AC, Perez-Rodriguez V, Ros-Cucurull E, Esojo A, Roncero C. Delayed Urinary Symptoms Induced by Ketamine. Journal of psychoactive drugs. 2018; 50(2):129–32. https://doi.org/10.1080/02791072.2017.1371364 PMID: 28994076

7. Shang HS, Wu YN, Liao CH, Chiueh TS, Lin YF, Chiang HS. Long-term administration of ketamine induces erectile dysfunction by decreasing neuronal nitric oxide synthase on cavernous nerve and increasing corporal smooth muscle cell apoptosis in rats. Oncotarget. 2017; 8(43):73670–83. https://doi.org/10.18632/oncotarget.10727 PMID: 29088735

8. Chang SR, Chang TC, Chen KY, Lin HH. Developing and validating a Taiwan version of the female sexual function index for pregnant women. The journal of sexual medicine. 2009; 6(6):1609–16. https://doi.org/10.1111/j.1743-6109.2009.01247.x PMID: 19473461

9. Yang SS, Wu C-H, Chen JY-J, Chang S-J. Assessment of ketamine uropathy. Urological Science. 2015; 26:3.

10. O’Leary MP, Sant GR, Fowler FJ Jr., Whitmore KE, Spolarich-Kroll J. The interstitial cystitis symptom index and problem index. Urology. 1997; 49(5A Suppl):S8–63.

11. Chou NH, Huang YJ, Jiann BP. The Impact of Illicit Use of Amphetamine on Male Sexual Functions. The journal of sexual medicine. 2015; 12(8):1694–702. https://doi.org/10.1111/jsm.12926 PMID: 26147855

12. Rosen RC, Cappelleri JC, Smith MD, Lipsky J, Pena BM. Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. International journal of impotence research. 1999; 11(6):319–26. PMID: 10637462

13. Chao JK, Hwang TI, Ma MC, Kuo WH, Liu JH, Chen YP, et al. A survey of obesity and erectile dysfunction of men conscripted into the military in Taiwan. The journal of sexual medicine. 2011; 8(4):1156–63. https://doi.org/10.1111/j.1743-6109.2010.02181.x PMID: 21269394

14. Suppiah B, Vicksnasingam B, Singh D, Narayanan S. Erectile Dysfunction among People Who Use Ketamine and Poly-Drugs. Journal of psychoactive drugs. 2016; 48(2):86–92. https://doi.org/10.1080/02791072.2016.1156790 PMID: 27014841

15. Chan WL, Wood DM, Dargan PI. Significant Misuse of Sildenafil in London Nightclubs. Substance use & misuse. 2015; 50(1):1390–4.

16. Chang T, Lin CC, Lin AT, Fan YH, Chen KK. Ketamine-Induced Uropathy: A New Clinical Entity Causing Lower Urinary Tract Symptoms. Lower urinary tract symptoms. 2012; 4(1):19–24. https://doi.org/10.1111/j.1757-5672.2011.00101.x PMID: 22676454

17. Jhang JF, Birder LA, Chancellor MB, Kuo HC. Patient characteristics for different therapeutic strategies in the management ketamine cystitis. Neurourology and urodynamics. 2017; 36(3):887–91. https://doi.org/10.1002/nau.22996 PMID: 26998599

18. Tam YH, Ng CF, Wong YS, Pang KK, Hong YL, Lee WM, et al. Population-based survey of the prevalence of lower urinary tract symptoms in adolescents with and without psychotropic substance abuse. Hong Kong medical journal = Xianggang yi xue za zhi. 2016; 22(5):454–63. https://doi.org/10.12809/hkmj154806 PMID: 27516568

19. Chen IC, Lee MH, Chen WC, Hu TC, Lin HY. Risk Factors of Lower Urinary Tract Syndrome among Ketamine Users. Lower urinary tract symptoms. 2017.

20. Ren L, Deng J, Min S, Peng L, Chen Q. Ketamine in electroconvulsive therapy for depressive disorder: A systematic review and meta-analysis. Journal of psychiatric research. 2018; 104:144–56. https://doi.org/10.1016/j.jpsychires.2018.07.003 PMID: 30077114